Your Supplier Says It’s GRAS. Can They Prove It?

Almost every spec sheet that crosses our desk has the same four letters on it somewhere. GRAS. Generally Recognized as Safe.

Most brands read it the way they read “kosher” or “non-GMO”: a box someone else already checked. For a lot of ingredients, that box was checked by the supplier itself, privately, with nobody at FDA ever looking at the file. That has been completely legal for decades. It may not stay that way much longer.

What FDA actually proposed

In August, FDA proposed turning its voluntary GRAS notification program into a mandatory one. Comments are due December 9. If the rule is finalized as written, it takes effect 60 days after publication, and companies get an 18-month compliance period after that.

The headlines called it the end of self-GRAS. That is close but not quite right, and the difference matters for how you respond. The proposal does not create an approval system. A GRAS notice tells FDA what a company has concluded and why. It is not an application for approval, and nothing gets banned on day one. What changes is that the private file becomes a filing, and a thin file becomes visible.

The part brands miss: GRAS covers a use, not an ingredient

Here is the misunderstanding we see most often. Brands treat GRAS as a property of the ingredient, like its color or its particle size. It isn’t. A GRAS conclusion covers a substance under specific intended conditions of use: a food category, a use level, a technical purpose. FDA’s own proposal says plainly that whether an exemption applies depends on the substance and its conditions of use, not on the ingredient’s name.

In practice, it looks like this. Say a supplier’s dossier covers their botanical extract in beverages at a modest dose per serving. Your bar uses four times that amount, in a food category that never appeared in the dietary exposure assessment. The spec sheet still says GRAS. Your use may not be covered by it at all.

Under the voluntary system, that gap stayed invisible until a retailer’s regulatory team started asking questions or a plaintiff’s firm went looking. Under a mandatory system, it gets much easier to find.

Who carries the risk

Ingredient suppliers will do most of the filing. Brands will carry most of the exposure. When a retailer pulls a product or a class action gets filed, the name on the front of the wrapper is yours, not your supplier’s.

The ingredients most likely to rest on self-affirmed conclusions are the newer, more functional ones: botanical and mushroom extracts, novel sweeteners, specialty proteins, and the hero add-ins that carry a bar’s front-of-pack story. The classic bar deck of nuts, dates, oats, cocoa and dairy protein is not where this problem lives. The trouble sits in the one or two ingredients that make your bar different, which is exactly where you can least afford it.

Expect the pipeline of new ingredients to slow, too. One former FDA regulator has predicted that removing self-affirmed GRAS will mean fewer ingredients reaching the market. If your 2027 roadmap depends on the next novel ingredient a supplier is pitching, build in more time.

The transition window rewards brands that are already shipping

One detail in the proposal deserves more attention than it has gotten. Substances already on the market under a self-affirmed conclusion could use a time-limited, streamlined submission instead of a full GRAS notice. To qualify, the filer has to show the use was already in interstate commerce before the rule took effect, and the submission has to be made within one year of the effective date. Even then, landing on FDA’s list does not mean FDA has found the substance to be GRAS, and the agency can still require a full notice later.

That creates two practical consequences.

First, proof of prior market use becomes an asset. Purchase orders, certificates of analysis, batch records, ship dates and retail invoices are the evidence. Your co-manufacturer’s production records are part of that file, so make sure you know how to get them.

Second, timing now belongs in the formulation conversation. A bar that launches after the final rule takes effect, built around a self-affirmed ingredient, does not get the streamlined path. That ingredient will need a full notice, and FDA review takes time.

Five things to do before December 9

1. Inventory every ingredient that isn’t a commodity. For each one, ask the supplier one direct question: is this use covered by an FDA “no questions” letter, a GRAS regulation, or a self-affirmed conclusion? The first two are exempt from new filing under the proposal. The third is where your work is.
2. Match the dossier to your formula. Get the covered use levels and food categories in writing and compare them to your actual bar. If your use falls outside the scope, you have a project, and it is better to find it now than in a retailer audit.
3. Ask every supplier what they plan to file and when. A supplier who can’t answer that question in December will not be ready when the compliance date arrives.
4. Lock down your market-use evidence. Keep dated records of first commercial shipment for every SKU and every functional ingredient in it.
5. Stop briefing launches around undocumented ingredients. If an ingredient can’t show you a file today, don’t make it the center of a product you plan to ship in 2027.

And if the rule touches your business, comment. The comment period is not only for ingredient manufacturers. Brands that use these ingredients have a stake in how the streamlined pathway and compliance dates get written.

The upside

This is not a bad rule for serious brands. A mandatory, public inventory makes a documented ingredient worth more and an undocumented one worth less. Brands that did their homework get to say so. The brands that get hurt are the ones that built a claim around an ingredient nobody checked.

So the question to ask your supplier is no longer “Is it GRAS?” It is “GRAS for what, at what level, and who has the file?”

This post is general industry commentary, not legal advice. Talk to your regulatory counsel about your specific ingredients.

Want a second set of eyes on your ingredient deck before the comment window closes? Our Innovation Center works through ingredient documentation as part of every formulation project. Get in touch.